fig4

Figure 4. Radiographic response after SBRT. The patient underwent SBRT and concurrent durvalumab and tremelimumab. At the 3-month mark, early imaging typically shows mild residual enhancement. However, the response often continues to evolve, with subsequent imaging revealing no residual enhancement, even without additional treatment. This indicates that radiation destroys tumor DNA, leading to genetically non-viable tumors when a sufficient dose is applied. The timeframe for radiographic response, however, can vary significantly. SBRT: Stereotactic body radiation therapy.